financetom
Business
financetom
/
Business
/
Infinity Natural Resources Q4 Earning Tops Consensus, Revenue Rises; Shares Jump
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Infinity Natural Resources Q4 Earning Tops Consensus, Revenue Rises; Shares Jump
Mar 11, 2026 7:13 AM

05:09 PM EDT, 03/10/2026 (MT Newswires) -- Infinity Natural Resources ( INR ) reported fiscal Q4 net income late Tuesday of $1.32 per diluted share.

Analysts polled by FactSet expected $0.64.

Revenue for the quarter ended Dec. 31 was $117.1 million, up from $69.1 million a year earlier.

Three analysts expected $109.3 million.

For fiscal 2026, the company expects development capital budget of $450 million to $500 million.

Shares rose around 3.7% in recent after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Commerzbank on Overnight News
Commerzbank on Overnight News
Oct 9, 2024
06:40 AM EDT, 10/09/2024 (MT Newswires) -- Commerzbank in its European Sunrise note of Wednesday highlighted: Markets: United States Treasuries better bid into New York close as break-evens hit new highs. Oil little changed, US equity futures soft, US dollar well supported. Fed: Federal Reserve Vice Chair Philip Jefferson is taking decisions meeting-by-meeting, risk to inflation and employment have been...
Ocugen Says FDA Lifts Clinical Hold for Diabetic Macular Edema Treatment Study
Ocugen Says FDA Lifts Clinical Hold for Diabetic Macular Edema Treatment Study
Oct 9, 2024
06:48 AM EDT, 10/09/2024 (MT Newswires) -- Ocugen ( OCGN ) said Wednesday that the US Food and Drug Administration had lifted the clinical hold on its investigational new drug application for the phase 1 trial of its experimental drug, OCU200, a recombinant fusion protein used to treat diabetic macular edema. The company said it also plans to explore additional...
Nobel chemistry prize 2024 goes to trio of protein pioneers
Nobel chemistry prize 2024 goes to trio of protein pioneers
Oct 9, 2024
* Baker, Hassabis and Jumper win Nobel chemistry prize * Prize awarded for work on the structure of proteins * Chemistry third award in this year's Nobel line-up * Prizes announced through course of week By Johan Ahlander, Niklas Pollard STOCKHOLM, Oct 9 (Reuters) - U.S. Scientists David Baker and John Jumper and Britain's Demis Hassabis won the 2024 Nobel...
XORTX Initiates Precision Medicine Program
XORTX Initiates Precision Medicine Program
Oct 9, 2024
06:32 AM EDT, 10/09/2024 (MT Newswires) -- XORTX Therapeutics ( XRTX ) , a late-stage clinical pharmaceutical company focused on developing therapies to treat progressive kidney disease, announced Wednesday that it has initiated a precision medicine program. On August 29, XORTX had announced that independent peer-reviewed research reported that genetic factors are linked to the over-expression of xanthine oxidase and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved